البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
IRBESARTAN
TEVA CANADA LIMITED
C09CA04
IRBESARTAN
300MG
TABLET
IRBESARTAN 300MG
ORAL
100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0131700003; AHFS:
APPROVED
2018-06-11
_TEVA-IRBESARTAN Page 1 of 40_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-IRBESARTAN Irbesartan tablets Tablets, 75, 150 and 300 mg, Oral Teva Standard Angiotensin II AT 1 Receptor Blocker Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Canada www.tevacanada.com Date of Initial Authorization September 14, 2009 Date of Revision: February 17, 2023 Submission Control Number: 271205 _TEVA-IRBESARTAN Page 2 of 40_ RECENT MAJOR LABEL CHANGES 7. WARNINGS AND PRECAUTIONS 07/2021 SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................ 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................... 5 4.1 Dosing Considerations _ ....................................................................................................................... 5 _ 4.2 Recommended Dose and Dosage Adjustment _ ........................................................................... 5 _ 4.4 Administration _ ................ اقرأ الوثيقة كاملة